ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Free cash flow margin
ResMed Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 28.8%. Over the past ten years it has ranged from 5.45% (fiscal 2022) to 32.1% (fiscal 2025); the current reading is higher than 92% of that period. That is above the Medical Instruments & Supplies industry median of 1.61% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 28.8% | (3.27) |
| FY2025 | 32.1% | 4.62 |
| FY2024 | 27.5% | 14.22 |
| FY2023 | 13.2% | 7.79 |
| FY2022 | 5.45% | (13.94) |
| FY2021 | 19.4% | (4.16) |
| FY2020 | 23.6% | 8.91 |
| FY2019 | 14.6% | (3.89) |
| FY2018 | 18.5% | 1.95 |
| FY2017 | 16.6% | (9.53) |
Against its own ten years
Low 5.45%
High 32.1%
Ten-year median
19.0%
Current reading's percentile
92
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RMD ResMed Inc. | 28.8% |
| COO The Cooper Companies, Inc. compare | 16.0% |
| ALC Alcon compare | 14.7% |
| BDX Becton, Dickinson and Company compare | 14.3% |
| RGEN Repligen Corporation compare | 14.1% |
| WST West Pharmaceutical Services, Inc. compare | 13.1% |
| MDLN Medline Inc. compare | 7.75% |
| BAX Baxter International Inc. compare | 7.11% |
| SOLV Solventum Corporation compare | −1.42% |
| Medical Instruments & Supplies industry median | 1.61% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement